Ozempic Improved Outcomes, QOL In Phase 3 Trial In Type 2 Diabetes, Peripheral Artery Disease

 

• Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD1
• Based on STRIDE trial data, presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo while simultaneously published today in The Lancet, Novo Nordisk submitted a label extension application accepted for review by the FDA
• Approximately 12 million people in the United States are impacted by PAD, a form of atherosclerotic disease, and one in four also have type 2 diabetes

https://www.prnewswire.com/news-releases/ozempic-semaglutide-injection-1-mg-showed-improved-functional-outcomes-and-health-related-quality-of-life-in-phase-3-stride-trial-in-adults-with-type-2-diabetes-and-peripheral-artery-disease-pad-presented-at-acc-2025-302414859.html